Robert Bissonnette, MD: Highlighting Recent Findings on Topical Treatments for Atopic Dermatitis


This interview at RAD 2024 featured a discussion by Bissonnette of recent data related to 4 topical drugs for patients with atopic dermatitis.

Robert Bissonnette, MD, Chief Executive Officer and medical director of Innovaderm Research, discussed additional research related to 4 topical therapy options for individuals with atopic dermatitis (eczema) covered in his conference talk ‘Topical therapy revolution.’

Bissonnette’s talk was given at the Revolutionizing Atopic Dermatitis (RAD) 2024 Annual Meeting in Chicago, Illinois. In the talk, he covered new or recent findings related to 4 specific topicals: crisaborole, ruxolitinib, tapinarof, and roflumilast.

“I went on to talk about roflumilast and tapinarof,” Bissonnette explained. “For roflumilast, the data had been presented in terms of efficacy and safety in patients 6 years of age and older. Recently, data was presented in a study conducted in a younger population…The study in the ages between 2 and 6 showed that the efficacy and safety was very similar.”

Bissonnette was asked about other data highlighted over the course of his RAD 2024 presentation. He noted another notable element about roflumilast.

“Among the 3 newest topical agents for atopic dermatitis, it is the only one that has been studied in patients with body surface area (BSA) up to 100%,” Bissonnette said. “So patients that you would think would be more amenable to systemic therapy were enrolled…It has not been presented yet, but we will get roflumilast data in terms of safety and efficacy for patients with very high BSA, comparing active to placebo.”

To learn more about these eczema therapies, view the full interview posted above.

The quotes used in this article were edited for the purposes of clarity.

Related Videos
Video 3 -  4 KOLs are featured in, "Collaborating with Specialists: Primary Care Clinician’s Evolving Role in HE Management"
Video 3 -  4 KOLs are featured in, "HE Experts on Symptoms, Risk Factors, Diagnosis Challenges, and Severity Grading"
© 2024 MJH Life Sciences

All rights reserved.